Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07751250
PHASE1
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function
Sponsor: Arcus Biosciences, Inc.
View on ClinicalTrials.gov
Summary
The purpose of the study is to compare the single dose PK of casdatifan between participants with moderate hepatic impairment (HI) and healthy matched control participants with normal hepatic function.
Official title: A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics of Casdatifan (AB521) in Participants With Moderate Hepatic Impairment Compared to Healthy Matched Participants
Key Details
Gender
All
Age Range
18 Years - 84 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2026-08
Completion Date
2027-05
Last Updated
2026-08-07
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Casdatifan
Participants will receive a 100 mg single oral dose of casdatifan.